Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Vaxcyte Inc
PCVX
Healthcare
Biotechnology
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation...
31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PCVX)
New Post
View:
Posts & Comments
Threaded Posts
(266)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 25, 2024 2:15am
Learn to Evaluate (PCVX) using the Charts
NEWS: $PCVX Learn to Evaluate (PCVX) using the Charts2024-11-25 00:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to
...more
(266)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 03, 2024 11:17am
Vaxcyte stock soars 35% on promising VAX-31 vaccine trial re
Just In: $PCVX Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results2024-09-03 10:10:31 ET Vaxcyte Inc (NASDAQ: PCVX) saw a remarkable 35% surge in its stock price during premarket trading
...more
Lahontan Gold Announces Filing of Santa Fe Technical Report
posted Nov 29, 2024 9:00am by
Lahontan Gold Corp.
-
|
Lahontan Gold is pleased to announce that the Company has filed on SEDAR+ an independent Technical Report and updated Mineral Resource Estimate ("MRE") titled "Santa Fe Project Technical Report," effective October 9, 2024, and dated November 27, 2024, for Lahontan's Santa Fe Mine gold and silver project, Santa Fe District, Mineral County, Nevada. ...read more
(266)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Sep 03, 2024 10:17am
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study o
News; $PCVX Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older-- At All Doses Studied, VAX-31
...more
(9)
•••
MikeTester
X
View Profile
View Bullboard History
Post by
MikeTester
on Aug 01, 2024 5:23pm
Vaxcyte, Inc. (PCVX): Pioneering Innovative Vaccines to Tack
https://beyondspx.com/2024/08/01/vaxcyte-inc-pcvx-pioneering-innovative-vaccines-to-tackle-bacterial-diseases/
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >